2-benzyl-2,3,4,9-tetrahydro-β-carboline-1-thione | 1161933-48-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-benzyl-2,3,4,9-tetrahydro-β-carboline-1-thione
• 英文别名: benzyl-2,3,4,9-tetrahydro-β-carbolin-1-thione；2-benzyl-4,9-dihydro-3H-pyrido[3,4-b]indole-1-thione
• CAS: 1161933-48-7
• 化学式: C₁₈H₁₆N₂S
• 分子量: 292.404
• InChiKey: ZDOBSVKARJYTHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  51.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-benzyl-2,3,4,9-tetrahydro-β-carboline-1-thione 在 碘代三甲硅烷 、 sodium hydride 作用下， 以 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 (2-benzyl-1-thioxo-1,2,3,4-tetrahydro-β-carbolin-9-yl)acetic acid
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of novel (1-thioxo-1,2,3,4-tetrahydro-β-carbolin-9-yl)acetic acids as selective inhibitors for AKR1B1

  摘要：

  New substituted (1-thioxo-1,2,3,4-tetrahydro-b-carbolin-9-yl) acetic acids were designed as the inhibitor of AKR1B1 based upon the structure of rhetsinine, a minor alkaloidal component of Evodia rutaecarpa, and twenty derivatives were synthesized and evaluated. The most active compound of the series was (2-benzyl-6-methoxy-1-thioxo-1,2,3,4-tetrahydro-b-carbolin-9-yl) acetic acid (7m), which showed comparable inhibitory activity for AKR1B1 (IC50 = 0.15 mu M) with clinically used epalrestat (IC50 = 0.1 mu M). In the view of activity and selectivity, the most potent compound was (2-benzyl-6-carboxy-1-thioxo1,2,3,4-tetrahydro-b-carbolin-9-yl) acetic acid (7t), which showed strong inhibitory effect (IC50 = 0.17 mu M) and very high selectivity for AKR1B1 against AKR1A1 (311: 1) and AKR1B10 (253: 1) compared with epalrestat. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.10.073
• 作为产物：
  描述：

  4,9-Dihydropyrano<3,4-b>indol-1(3H)-on 在 劳森试剂 作用下， 以 甲苯 为溶剂， 生成 2-benzyl-2,3,4,9-tetrahydro-β-carboline-1-thione
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of novel (1-thioxo-1,2,3,4-tetrahydro-β-carbolin-9-yl)acetic acids as selective inhibitors for AKR1B1

  摘要：

  New substituted (1-thioxo-1,2,3,4-tetrahydro-b-carbolin-9-yl) acetic acids were designed as the inhibitor of AKR1B1 based upon the structure of rhetsinine, a minor alkaloidal component of Evodia rutaecarpa, and twenty derivatives were synthesized and evaluated. The most active compound of the series was (2-benzyl-6-methoxy-1-thioxo-1,2,3,4-tetrahydro-b-carbolin-9-yl) acetic acid (7m), which showed comparable inhibitory activity for AKR1B1 (IC50 = 0.15 mu M) with clinically used epalrestat (IC50 = 0.1 mu M). In the view of activity and selectivity, the most potent compound was (2-benzyl-6-carboxy-1-thioxo1,2,3,4-tetrahydro-b-carbolin-9-yl) acetic acid (7t), which showed strong inhibitory effect (IC50 = 0.17 mu M) and very high selectivity for AKR1B1 against AKR1A1 (311: 1) and AKR1B10 (253: 1) compared with epalrestat. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.10.073

文献信息

• Synthesis of new tricyclic thiolactams as potent antitumor agent for pancreatic cancer
  作者：Takuya Okada、Daisuke Minehira、Minetatsu Takada、Hirokazu Urata、Atsushi Kato、Isao Adachi、Yukiko Kurashima、Satoshi Kaji、Tsutomu Ogura、Shigeki Chiba、Hiroyasu Esumi、Naoki Toyooka

  DOI：10.1016/j.bmcl.2016.04.035

  日期：2016.6

  medium (NDM) and Dulbecco's modified Eagle's medium (DMEM) was evaluated against a human pancreatic cancer cell line PANC-1. Among the tested compounds, the 4'-hydroxy derivative 3d showed the most potent cytotoxicity in NDM (PC50 1.68μM) although the moderate preferential cytotoxicity (PC50 1.68μM in NDM vs PC50 20μM in DMEM). The 3'-hydroxy derivative 3e exhibited the most preferential cytotoxicity

  我们合成了新颖的三环硫代内酰胺2a-d，3d-k，在吲哚亚基的氮原子上具有苄基或取代的苄基取代基，并且它们在营养剥夺性培养基（NDM）和Dulbecco改良的Eagle培养基（DMEM）下的优先细胞毒性为针对人胰腺癌细胞系PANC-1进行了评估。在测试的化合物中，4'-羟基衍生物3d在NDM中表现出最强的细胞毒性（PC50为1.68μM），尽管中等程度的优先细胞毒性（在NDM中为PC501.68μM，而在DMEM中为PC5020μM）。3'-羟基衍生物3e表现出最优先的细胞毒性（NDM中的PC50为1.96μM，而DMEM中的30μM时抑制小于50％）。苄基2a和卤代苄基衍生物2b，c在NDM中无细胞毒性。此外，吲哚（10，PC50173.7μM），内酯（11，PC50131.7μM），内酰胺（12，PC5044.8μM）衍生物在NDM中显示出一周或中等的细胞毒性。这些结果表明苄基取代基和
• FUSED TRICYCLIC COMPOUND HAVING ALDOSE REDUCTASE INHIBITORY ACTIVITY
  申请人：TOYOOKA Naoki

  公开号：US20100145052A1

  公开（公告）日：2010-06-10

  A fused tricyclic compound having aldose reductase inhibitory activity and shown by the following formula, wherein R 1 represents 1 to 3 atoms or substituents selected from a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl, cycloalkyl, alkylene, or alkoxy group, and a protected or unprotected hydroxyl or carboxyl group, R 2 represents a protected or unprotected carboxyl group, R 3 represents 1 or 2 atoms or substituents selected from a hydrogen atom, a halogen atom, an oxo group, a substituted or unsubstituted alkyl or alkoxy group, and a protected or unprotected carboxyl group, A represents an alkylene group, and B represents an oxygen atom, a sulfur atom, or a group shown by the following formula, wherein R 4 represents an alkyl or aryl group substituted by an aryl, cycloalkyl, or heterocyclic group, and X represents an oxygen atom or a sulfur atom, provided that, when B represents a group shown by the following formula: wherein R 4 represents an alkyl or aryl group substituted with an aryl, cycloalkyl, or heterocyclic group, X represents a sulfur atom.

  具有醛还原酶抑制活性的熔合三环化合物，其化学式如下：其中，R1代表1至3个原子或取代或未取代的烷基，环烷基，烷基，或烷氧基，以及受保护或未受保护的羟基或羧基中的一个或多个，或氢原子或卤素原子；R2代表受保护或未受保护的羧基；R3代表1或2个原子或取代或未取代的烷基，烷氧基，卤素原子，氧代基，或受保护或未受保护的羧基中的一个或多个，或氢原子；A代表烷基；B代表氧原子，硫原子，或由以下化学式表示的基团：其中，R4代表取代有芳基，环烷基，或杂环基团的烷基或芳基基团，X代表氧原子或硫原子，但当B代表由以下化学式表示的基团时：其中，R4代表取代有芳基，环烷基，或杂环基团的烷基或芳基基团，X代表硫原子。
• US8198447B2
  申请人：——

  公开号：US8198447B2

  公开（公告）日：2012-06-12
• Design, synthesis, and biological evaluation of novel (1-thioxo-1,2,3,4-tetrahydro-β-carbolin-9-yl)acetic acids as selective inhibitors for AKR1B1
  作者：Daisuke Minehira、Daisuke Takeda、Hirokazu Urata、Atsushi Kato、Isao Adachi、Xu Wang、Yuji Matsuya、Kenji Sugimoto、Mayuko Takemura、Satoshi Endo、Toshiyuki Matsunaga、Akira Hara、Jun Koseki、Kayo Narukawa、Shuichi Hirono、Naoki Toyooka

  DOI：10.1016/j.bmc.2011.10.073

  日期：2012.1

  New substituted (1-thioxo-1,2,3,4-tetrahydro-b-carbolin-9-yl) acetic acids were designed as the inhibitor of AKR1B1 based upon the structure of rhetsinine, a minor alkaloidal component of Evodia rutaecarpa, and twenty derivatives were synthesized and evaluated. The most active compound of the series was (2-benzyl-6-methoxy-1-thioxo-1,2,3,4-tetrahydro-b-carbolin-9-yl) acetic acid (7m), which showed comparable inhibitory activity for AKR1B1 (IC50 = 0.15 mu M) with clinically used epalrestat (IC50 = 0.1 mu M). In the view of activity and selectivity, the most potent compound was (2-benzyl-6-carboxy-1-thioxo1,2,3,4-tetrahydro-b-carbolin-9-yl) acetic acid (7t), which showed strong inhibitory effect (IC50 = 0.17 mu M) and very high selectivity for AKR1B1 against AKR1A1 (311: 1) and AKR1B10 (253: 1) compared with epalrestat. (C) 2011 Elsevier Ltd. All rights reserved.